NCT06579898

Brief Summary

Thanks to improved healthcare, the life expectancy of people with ID is increasing and is approaching that of the general population. Several studies have shown that most cardiovascular disease (CVRF) risk factors are as common or even more common in people with ID than in the general population. The guidelines of the American College of Sport Medicine (ACSM) state that a resistance training (RT) programme can can effectively reduce CVRF if performed at a high intensity. A secondary benefit of RT is the increase in muscle strength and muscle mass that can reduce and can improve the ability to perform activities of daily living (ADL), also two common problems in people with ID.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Dec 2021

Typical duration for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2021

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

March 7, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 30, 2024

Completed
Last Updated

August 30, 2024

Status Verified

August 1, 2024

Enrollment Period

2.6 years

First QC Date

March 7, 2024

Last Update Submit

August 28, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • Glycated Haemoglobin

    mmol/mol, Outcome is measured with blood samples and analysed in a laboratory of ErasmusMC

    through study completion, an average of 1 year

  • Systolic blood pressure

    mm/Hg, Blood pressure is measured with a digital blood pressure device

    through study completion, an average of 1 year

  • LDL cholesterol

    mmol/L, Outcome is measured with blood samples and analysed in a laboratory of ErasmusMC

    through study completion, an average of 1 year

  • Waist-hip ratio

    cm, Waist-hip ratio is calculated after measuring waist circumference and hip circumference with a flexible tape measure.

    through study completion, an average of 1 year

Secondary Outcomes (9)

  • Triglycerides

    through study completion, an average of 1 year

  • HDL cholesterol

    through study completion, an average of 1 year

  • Total cholesterol

    through study completion, an average of 1 year

  • Glucose

    through study completion, an average of 1 year

  • Muscle strength

    through study completion, an average of 1 year

  • +4 more secondary outcomes

Study Arms (1)

PRET

EXPERIMENTAL

All participants participate in a progressive resistance exercise training programme for 24 weeks.

Other: Progressive resistance exercise training

Interventions

A 24-week progressive strength training programme (PRET). Divided into 4 mesocycles in which the intensity of training is built up from 60% 1RM- 80% 1RM. Training is carried out twice a week under the guidance of a physiotherapist or exercise instructor.

PRET

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • being 18 years or older;
  • living in a residential facility or receiving care from one of the participating care providers;
  • diagnosed with mild (IQ = 50-69) or moderate (IQ = 35-49) ID;
  • diagnosed with metabolic syndrome, or at least two of the following CVRF: hypertension, hypercholesterolemia, diabetes mellitus type 2, or obesity.
  • participants must be able to walk independently and able to follow instructions on posture and performance for good execution of the exercises

You may not qualify if:

  • not able to follow instructions or physical limitations interfering with participation in training programme

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Amarant

Tilburg, North Brabant, 5037LD, Netherlands

Location

Abrona

Huis Ter Heide, South Holland, 3712XA, Netherlands

Location

Ipse de Bruggen

Zoetermeer, South Holland, 2719EK, Netherlands

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2HypertensionHypercholesterolemiaObesity

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesVascular DiseasesCardiovascular DiseasesHyperlipidemiasDyslipidemiasLipid Metabolism DisordersOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Alyt Oppewal, Dr

    Erasmus Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Investigator

Study Record Dates

First Submitted

March 7, 2024

First Posted

August 30, 2024

Study Start

December 1, 2021

Primary Completion

July 1, 2024

Study Completion

July 1, 2024

Last Updated

August 30, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will share

Study protocol has been published. Further information can be requested.

Shared Documents
STUDY PROTOCOL
Time Frame
Study Protocol is available Elbers RG, de Oude KI, Kastanidis T, Maes-Festen DAM, Oppewal A. The Effect of Progressive Resistance Exercise Training on Cardiovascular Risk Factors in People with Intellectual Disabilities: A Study Protocol. Int J Environ Res Public Health. 2022 Dec 8;19(24):16438. doi: 10.3390/ijerph192416438. PMID: 36554319; PMCID: PMC9778210.
Access Criteria
Open access

Locations